Merck Wins First Femur-Related Fosamax Suit

Law360, New York (April 29, 2013, 8:28 PM EDT) -- Merck & Co. on Monday triumphed in a New Jersey bellwether trial over femur fractures allegedly caused by its bone drug Fosamax, after a jury ruled that the nature of the plaintiff’s injury ruled out Fosamax as a potential cause.

A New Jersey federal jury found for the drugmaker, deciding plaintiff Bernadette Glynn’s femur fracture could not have been caused by Fosamax, a drug prescribed to treat diminished bone density, agreeing that Glynn’s fracture was consistent with a traumatic injury rather than compromised bone health. The...
To view the full article, register now.